Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its target price lowered by research analysts at Morgan Stanley from $146.00 to $136.00 in a report released on Thursday. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Morgan Stanley’s price objective indicates a potential upside of 11.82% from the stock’s current price.
ZBH has been the topic of a number of other research reports. BMO Capital Markets reissued a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet Holdings in a research report on Tuesday, July 11th. Guggenheim raised Zimmer Biomet Holdings from a “neutral” rating to a “buy” rating and set a $157.00 price target on the stock in a research report on Wednesday, July 12th. Needham & Company LLC reissued a “strong-buy” rating and set a $153.00 price target on shares of Zimmer Biomet Holdings in a research report on Wednesday, July 12th. Canaccord Genuity reissued a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 14th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $135.60.
Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter in the previous year, the business earned $1.79 EPS. The business’s revenue for the quarter was down .8% on a year-over-year basis.
TRADEMARK VIOLATION NOTICE: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/02/morgan-stanley-trims-zimmer-biomet-holdings-inc-zbh-target-price-to-136-00.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bronfman E.L. Rothschild L.P. grew its stake in Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 167 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in Zimmer Biomet Holdings by 3.9% during the 2nd quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 33 shares in the last quarter. Parallel Advisors LLC grew its stake in Zimmer Biomet Holdings by 20.8% during the 1st quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after purchasing an additional 199 shares in the last quarter. IHT Wealth Management LLC grew its stake in Zimmer Biomet Holdings by 28.4% during the 1st quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 256 shares in the last quarter. Finally, BB&T Investment Services Inc. acquired a new position in Zimmer Biomet Holdings during the 2nd quarter worth $144,000. 85.26% of the stock is owned by hedge funds and other institutional investors.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.